Companies Dominating the Complement 3 Glomerulopathy Landscape
- Novartis AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Apellies Pharmaceutical
- Amyndas Pharmaceuticals SA
- Kira Pharmaceuticals
- Alexion Pharmaceuticals Inc.
- Omeros Corporation
- Amgen Inc.
- Sobi®
- Boehringer Ingelheim International GmbH.
- AstraZeneca
Browse Key Market Insights with Data Illustration:
In the News
- Positive topline findings from the six-month, double-blind Phase III APPEAR-C3G study of iptacopan for the treatment of patients with C3 glomerulopathy (C3G)1 were released by Novartis today. The primary goal of the research was achieved, as iptacopan (200 mg twice daily) showed superiority over placebo in reducing proteinuria (protein in urine) on top of background medication in a way that was both clinically relevant and statistically significant at six months1. Iptacopan's safety profile matched data1-3 that had previously been published.
- Positive findings from the Phase 2 NOBLE study examining pegcetacoplan for the treatment of post-transplant recurrence of primary immune complex membranproliferative glomerulonephritis (IC-MPGN) and C3 glomerulopathy (C3G) will be presented at the Kidney Week Annual Meeting of the American Society of Nephrology (ASN), from Sobi® and Apellis Pharmaceuticals, Inc.
